{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.62","upperLimit":"21.74","value":"16.2"},{"groupId":"OG001","lowerLimit":"13.22","upperLimit":"23.27","value":"17.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"241"}],"units":"Participants"}],"description":"Objective response is defined as a CR or PR as determined by the Investigator using RECIST v1.1 on 2 consecutive occasions at least 6 weeks apart. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \\<10 mm). No new lesions. At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR. No new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Docetaxel 75 milligrams per square meter (mg/m\\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG000","title":"Docetaxel"},{"description":"Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG001","title":"Atezolizumab"}],"paramType":"NUMBER","populationDescription":"The TC1/2/3 or IC1/2/3 subgroup of PP","reportingStatus":"POSTED","timeFrame":"Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)","title":"Percentage of Participants With Objective Response as Determined Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}